Mucinous Ovarian Cancer : Symptoms, Treatment & Care

What Is Mucinous Ovarian Cancer?

Mucinous ovarian cancer accounts for 3-5% of epithelial ovarian malignancies. This type is characterized by tumor cells that produce a significant amount of mucus, leading to the formation of gelatinous cysts often measuring over 10-20 cm in size. Mucinous ovarian cancer typically originates either de novo in the ovary or from borderline mucinous tumors. It is notably different from high-grade serous carcinoma due to its gastrointestinal-like histology, lower mitotic rate, and infrequent TP53 mutations. Women diagnosed with this cancer are generally younger (under 50 years old) and tend to present with earlier-stage disease compared to those with serous types. However, it is important to rule out gastrointestinal metastases during diagnosis.

Symptoms and Signs of Mucinous Ovarian Cancer

Patients commonly experience progressive abdominal distension due to large cysts, which can be accompanied by bloating, discomfort, or a palpable mass that can be felt during a self-exam. Additional symptoms may include pelvic pressure, early satiety due to stomach compression, urinary frequency due to bladder involvement, and nonspecific digestive issues such as nausea or changes in bowel movements. In advanced cases, complications like bowel obstruction, pseudomyxoma peritonei (mucus ascites), or cyst rupture can lead to acute pain and require urgent medical intervention.

Causes and Risk Factors

The exact cause of mucinous ovarian cancer remains unclear. However, it is linked to younger age, larger tumor sizes, and potential origins from intestinal epithelium, unlike serous cancers, which typically arise from fallopian tube precursors. Unlike serous subtypes, BRCA1/2 mutations are exceedingly rare in mucinous ovarian cancer; instead, KRAS mutations are present in up to 50% of cases and contribute to its slower progression. Modifiable risk factors include obesity and a history of smoking; however, the evidence connecting these factors to mucinous ovarian cancer is associative rather than causative. Protective factors, similar to general ovarian cancer patterns, include having multiple pregnancies (multiparity) and the use of oral contraceptives.

Diagnosis and Staging

The initial evaluation for mucinous ovarian cancer includes measuring tumor markers such as CA-19-9, which is often more reliable than CA-125 (which may be normal). Transvaginal ultrasound typically reveals multilocular cystic masses, and contrast-enhanced CT or MRI scans assess the extent of the disease and rule out gastrointestinal primary tumors. A definitive diagnosis requires surgical exploration along with frozen section analysis. Comprehensive staging includes omentectomy, appendectomy, and peritoneal biopsies per FIGO guidelines. Early imaging aids in optimal cytoreduction, and a multidisciplinary review is essential to distinguish primary ovarian disease from metastatic disease, which is critical for prognosis.

Treatment Options for Mucinous Ovarian Cancer

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

The cornerstone of treatment is comprehensive surgical staging combined with maximal tumor debulking, aiming for no gross residual disease, even in extensive cases that may require bowel resection. Adjuvant chemotherapy with carboplatin and paclitaxel generally yields disappointing response rates (10-20%) and progression-free survival rates (12-15 months). This has prompted the investigation of non-platinum regimens, such as FOLFOX (5-FU, leucovorin, oxaliplatin), borrowed from colorectal cancer protocols. Targeted therapies show promise; for instance, bevacizumab has been shown to improve progression-free survival by 3-6 months in advanced cases. Other targeted agents include multi-kinase inhibitors like nintedanib, HER2-directed therapies such as trastuzumab for amplified cases, and MEK inhibitors that address specific molecular vulnerabilities. Clinical trials are essential due to the rarity of this cancer.

Prognosis and Survival Rate

• •Localized Stage I-II
  Has a 5-year overall survival rate of 80-91%, significantly higher than that of serous types (47%). The 10-year survival rates are approximately 70-80%, reflecting its indolent nature.
• •Advanced Stage III-IV
  Has a 5-year survival rate of 30-50%, largely due to chemoresistance and late recurrence, despite initial successful surgical intervention.

Several factors can influence prognosis. Advanced stage at diagnosis (greater than stage II), suboptimal cytoreduction (more than 1 cm of residual tumor), and the presence of pseudomyxoma peritonei are associated with poorer outcomes. Conversely, complete resection, being younger at diagnosis, and access to targeted therapies—such as anti-angiogenics—significantly extend survival. Molecular profiling for KRAS and HER2 alterations can help guide personalized treatment, and nutritional optimization supports recovery from aggressive surgery.

Why Choose Everhope for Mucinous Ovarian Cancer Care

Everhope Oncology specializes in managing rare cancer subtypes through expert gynecologic oncologists who are skilled in performing fertility-sparing and ultra-radical cytoreductions tailored to mucinous pathology. Our integrated programs offer molecular tumor board evaluations, trial enrollment for innovative anti-angiogenic therapies, functional nutrition support with IV micronutrients to combat malnutrition resulting from mucus-related complications, plus patient navigation to enhance quality of life.